Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Recruiting

• Conditions: Pediatric Solid Tumors

• Registration Number: NCT06171971
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of \< 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-20
• Study First Submitted: 2022-09-06
• Status Verified: 2023-12
• Primary Completion: 2023-12
• Study Completion: 2023-12
• Study First Submitted QC: 2023-12-12
• Last Update Submitted: 2023-12-12
• Study First Posted: 2023-12-15
• Last Update Posted: 2023-12-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retrospective description of the clinical and therapeutic impact of the systematic performance of molecular analyzes on solid tumors	up to 12 months	The aim of this retrospective study is to improve and harmonize international practices

Trial Locations

Locations (1)

Service d'onco-hématologie pédiatrique - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France